Stryker Corporation (SYK)

Currency in USD
276.78
+1.38(+0.50%)
Real-time Data·
SYK is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
271.67277.98
52 wk Range
267.00392.55
Key Statistics
Prev. Close
275.4
Open
277.98
Day's Range
271.67-277.98
52 wk Range
267-392.55
Volume
1.47M
Average Volume (3m)
2.61M
1-Year Change
-26.2117%
Book Value / Share
62.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SYK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
366.15
Upside
+32.29%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 16 consecutive years

Stryker Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

23 Buy
6 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 366.15
(+32.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Baird
Buy385.00+39.14%-MaintainOct 07, 2026
Barclays
Buy375.00+35.53%-New CoverageOct 06, 2026
Truist Securities
Hold310.00+12.04%340.00MaintainOct 06, 2026
Needham
Buy418.00+51.07%-MaintainOct 06, 2026
Stifel
Buy330.00+19.27%360.00MaintainSep 29, 2026

Stryker Corporation SWOT Analysis


Strategic Reshaping
Explore Stryker's portfolio transformation, including the Inari Medical acquisition and Spinal Implants divestiture, aimed at high-growth market segments
Robotic Surgery Leade
Delve into Stryker's dominance in robotic surgery with the Mako system, driving innovation and market share in orthopedic procedures
Financial Resilience
Discover Stryker's robust financial performance, with double-digit revenue growth and margin expansion, despite industry challenges
Analyst Optimism
Learn about analyst perspectives, with price targets ranging from $435 to $450, reflecting confidence in Stryker's growth potential
Read full SWOT analysis

Stryker Corporation Earnings Call Summary for Q2/2026

  • Stryker Q2 2026 results beat estimates with adjusted EPS of $3.69 vs. $3.49 expected and revenue of $6.6B; shares fell 9.23% after-hours to $315.90.
  • Organic sales grew 9.0% with adjusted operating margin expanding 170 bps to 27.4%; recovery continued from earlier cybersecurity incident disruption.
  • Full-year guidance narrowed to 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS, signaling limited upside room despite strong Q2 beat.
  • Mako robotic platform achieved record Q2 installations, surpassing 2.5M procedures globally; new Mako RPS partial knee system launched commercially.
  • Management expects strong H2 driven by capital equipment demand and elevated backlog, but faces execution risks from supply disruptions and cyber remediation costs.
Last Updated: 2026/07/30, 23:40
Read Full Transcript

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
3,69 / 3,49
Revenue / Forecast
6,6B / 6,58B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 9.65%
Dividend Yield
1.28%
Industry Median 1.44%
Annualised payout
3.52
Paid quarterly
5-Years Growth
+7.14%
Growth Streak

SYK Income Statement

Compare SYK to Peers and Sector

Metrics to compare
SYK
Peers
Sector
Relationship
P/E Ratio
28.2x27.2x−0.3x
PEG Ratio
1.020.320.00
Price/Book
4.4x2.8x2.6x
Price / LTM Sales
4.1x2.0x3.0x
Upside (Analyst Target)
33.0%0.0%57.9%
Fair Value Upside
Unlock30.5%7.6%Unlock

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
140,61M36,66%38,72B
Other Institutional Investors
174,29M45,44%48,00B
Public Companies & Retail Investors
68,68M17,91%18,91B
Total
383,57M100,00%105,64B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7,15%27 414 7427 550 020
Vanguard Capital Management, LLC6,38%24 474 2206 740 200

FAQ

What Is the Stryker (SYK) Stock Price Today?

The Stryker stock price today is 276,78 USD.

What Stock Exchange Does Stryker Trade On?

Stryker is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Stryker?

The stock symbol for Stryker is "SYK."

Does Stryker Pay Dividends? What’s The Current Dividend Yield?

The Stryker dividend yield is 1.28%.

What Is the Stryker Market Cap?

As of today, Stryker market cap is 105,46B USD.

What Is Stryker's Earnings Per Share (TTM)?

The Stryker EPS (TTM) is 9,65.

When Is the Next Stryker Earnings Date?

Stryker will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is SYK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Stryker Stock Split?

Stryker has split 9 times.

How Many Employees Does Stryker Have?

Stryker has 56000 employees.

What is the current trading status of Stryker (SYK)?

As of Oct 08, 2026, Stryker (SYK) is trading at a price of 276,78 USD, with a previous close of 275,40 USD. The stock has fluctuated within a day range of 271,67 USD to 277,98 USD, while its 52-week range spans from 267,00 USD to 392,55 USD.

What Is Stryker (SYK) Price Target According to Analysts?

The average 12-month price target for Stryker is 366,15 USD, with a high estimate of 465 USD and a low estimate of 298 USD. 23 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +32,29% Upside potential.

What Is the SYK Premarket Price?

SYK's last pre-market stock price is 276,50 USD. The pre-market share volume is 670,00, and the stock has decreased by 1,10, or 0,40%.

What Is the SYK After Hours Price?

SYK's last after hours stock price is 275,54 USD, the stock has decreased by 0,14, or 0,05%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.